Interferon-β treatment requires B cells for efficacy in neuro-autoimmunity.

Recombinant interferon-β (IFN-β) remains the most widely prescribed treatment for relapsing remitting multiple sclerosis (RRMS). Despite widespread use of IFN-β, the therapeutic mechanism is still partially understood. Particularly, the clinical relevance of increased B cell activity during IFN-β tr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunol
Main Authors: Schubert, Ryan D., Hu, Yang, Kumar, Gaurav, Szeto, Spencer, Abraham, Peter, Winderl, Johannes, Guthridge, Joel M., Pardo, Gabriel, Dunn, Jeffrey, Steinman, Lawrence, Axtell, Robert C.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4340715/
https://ncbi.nlm.nih.gov/pubmed/25646307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1402029
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki